| http://www.w3.org/ns/prov#value | - ???We are very excited to be acquiring SKS Ocular???s technology, which we see as complementary to our efforts to develop and commercialize Squalamine Eye Drops for retinal disease,??? stated Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical. ???This acquisition is a continuation of our strategy to build out a robust pipeline with novel, innovative delivery technologies.
|
